

Protherics

[View the current Protherics Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/8617-Protherics.html>)

Contact Details:

The Health Business and Technical Park
Runcorn
Cheshire
W47 4QF
United Kingdom

Tel: 01928 518 000
Fax: 01928 518 002
Email: barry.riley@protherics.com

We are a biopharmaceutical business, with approximately 125 employees and operations in the United Kingdom, United States and Australia. We are focused on immunotherapeutic research and development, and were formed in September 1999 through the merger of Proteus International Plc and Therapeutic Antibodies Inc.

Our products are based on two proprietary technology platforms:

Highly purified polyclonal antibodies for acute medical emergency applications. These products are in late stage development or already on the market and include CroFab™, DigiFab™ and CytoTAb® .

Novel peptide-conjugate vaccines to treat chronic diseases. These products are in pre-clinical or clinical development and include GnRH(gonadotropin releasing hormone) and angiotensin vaccines.

Recent Publications by Protherics:



- [Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function.](#)
*Glucarpidase (formerly known as carboxypeptidase G2 or CPG2) is being...*20th May, 2008
Protherics PLC, The Heath Business & Technical Park, Runcorn, Cheshire,- J Clin Pharmacol. 2008 Mar;48(3):279-84. Epub 2008 Jan 11. ([DOI Direct Link](#))
- [Optimal conditions for the papain digestion of polyclonal ovine IgG for the production of bio-therapeutic Fab fragments.](#)
*In the present paper, we describe a rapid method for the determination of...*8th March, 2008
Process Development Group, Protherics U.K. Ltd, Blaenwaun, Ffostrasol,- Biotechnol Appl Biochem. 2005 Oct;42(Pt 2):163-8. ([DOI Direct Link](#))
- [Antibody production: polyclonal-derived biotherapeutics.](#)
*Antibody based therapies using monoclonal or polyclonal antibodies are...*22nd May, 2007
Process Development Group, Protherics UK Ltd, Blaenwaun, Ffostrasol,- J Chromatogr B Analyt

- Technol Biomed Life Sci. 2007 Mar 15;848(1):2-7. ([DOI Direct Link](#))
- [Optimised affinity purification of polyclonal antibodies from hyper immunised ovine serum using a synthetic Protein A adsorbent, MAbsorbent A2P.](#)
This report describes the applicability of a synthetic chromatography... 19th May, 2005
 Process Development Group, Protherics Ltd., Blaenwaun, Ffostrasol,- J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jan 25;814(2):209-15. ([DOI Direct Link](#))
 - [Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure \(hypertension\) in man.](#)
AIMS: We aim to modulate the renin-angiotensin system (RAS) by active... 3rd February, 2004
 Protherics plc. (PMD), The Heath Business & Technical Park, Runcorn, UK.- Br J Clin Pharmacol. 2003 Nov;56(5):505-12.

BioNews Results for Protherics



- [ReNeuron appoints Bryan Morton as Non-executive Director](#)
Pharma Live: Nov 27 2008 2:45PM Matching: protherics
- [Protherics begins submission of rolling BLA for Voraxaze](#)
PharmaBiz: Nov 25 2008 12:06PM Matching: protherics
- [Protherics initiates BLA submission for Voraxaze](#)
Pharmaceutical Business Review: Nov 25 2008 6:37AM Matching: protherics
- [Protherics Announces Interim Results for Six Months Ended 30 September 2008](#)
Pharma Live: Nov 21 2008 2:37AM Matching: protherics
- [FDA Sends Letter to Protherics Over Voraxaze Web Material](#)
Pharma Live: Nov 20 2008 10:50PM Matching: protherics
- [Protherics PLC Announces Regulatory Application](#)
Therapeutics Daily: Nov 20 2008 1:20PM Matching: protherics
- [Protherics PLC announces Regulatory Application](#)
Genetic Engineering News: Nov 20 2008 9:26AM Matching: protherics
- [Protherics PLC announces Interim Results](#)
Genetic Engineering News: Nov 20 2008 9:26AM Matching: protherics
- [Protherics PLC announces Interim Results](#)
Genetic Engineering News: Nov 20 2008 7:41AM Matching: protherics
- [Protherics PLC announces Regulatory Application](#)
Genetic Engineering News: Nov 20 2008 7:41AM Matching: protherics
- [Protherics PLC announces Delisting from NASDAQ](#)
Genetic Engineering News: Nov 14 2008 5:41PM Matching: protherics
- [UPDATE:BTG Beats Half-Year Expectations;Expects Revenue Boost 2012](#)
Morningstar.com: Nov 12 2008 11:25AM Matching: protherics
- [UPDATE:BTG Beats Half-Year Expectations;Expects Revenue Boost 2012](#)
CNN Money: Nov 12 2008 11:03AM Matching: protherics
- [UPDATE:BTG Beats Half-Year Expectations;Expects Revenue... \(DJ\)](#)
Easy Bourse: Nov 12 2008 11:47AM Matching: protherics
- [UPDATE:BTG Beats Half-Yr Expectations;Expects Rev Boost 2012](#)
Wall Street Journal Online: Nov 12 2008 11:05AM Matching: protherics



Protherics Patents:

- 7378489- [Angiotensin derivatives](#)
- 6833131- [Antivenom immunesera](#)
- 6262069- [1-amino-7-isoquinoline derivatives as serine protease inhibitors](#)
- 6193969- [Antibody fragments in therapy](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10
Copyright 1997-2008 - BioPortfolio Limited.

